Congruence Therapeutics News and Activities

Acquisition, funding and merger involving Congruence Therapeutics.

• Congruence Therapeutics has just announced a $40 Million fundraising (posted on March 25 2026).

View the org chart displaying its 21 main executives

Most searched biographies at Congruence Therapeutics

• Clarissa Desjardins, Chief Executive Officer
• Nancy Harrison, Director
• Didier Leconte, Director

Popular executive movements at Congruence Therapeutics

• Maximilian Ebert, who was Director, Computational Molecular Sciences, is promoted to Vice President, Computational Molecular Sciences  (posted on March 25 2026).

Create your alert
to follow the executive moves at Congruence Therapeutics.

Congruence Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Congruence Therapeutics

• Congruence Announces Participation at the 2026 Bloom Burton & Co. Healthcare Investor Conference
• Congruence Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
• Congruence Announces $39.5M Financing to Advance Portfolio of Small Molecule Correctors into the Clinic
• Congruence Announces First Dosing in Phase 1/1b Clinical Trial of CGX-926, a First-in-Class Oral MC4R Corrector for Genetic Obesity
• Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs
• Congruence Therapeutics to Present Preclinical Characterization of its MC4R Corrector Development Candidate CGX-926 for Genetic Obesity at ObesityWeek 2025
• Congruence Therapeutics Earns "Fierce 15" Distinction for 2025
• Congruence Therapeutics Announces Closing of $32M Financing to Advance First-in-Class Genetic Obesity Candidate Drug CGX-926 Through Phase 1b Proof of Concept Clinical Trial
• Congruence Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to Advance Novel GCase Activators and Correctors for Parkinson's Disease with GBA1 Mutations
• Congruence Therapeutics Announces Oral Presentation on MC4R Corrector Development Candidate CGX-926 for Early-Onset Obesity at the 3rd Annual Obesity & Weight Loss Drug Development Summit
• View more press releases Close

Social media about Congruence Therapeutics

• Congruence Therapeutics on Wikipedia, Google News & Yahoo Finance
• Congruence Therapeutics on LinkedIn, X (Twitter) & YouTube